PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

NCT04787302 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: CVL-231
DRUG: CVL-231
DRUG: CVL-231

Sponsor

Cerevel Therapeutics, LLC